Published in Blood Weekly, February 24th, 2005
"A global method is proposed for therapeutic drug monitoring of atazanavir, a novel protease inhibitor and of all other protease inhibitors (PI) and non nucleoside reverse transcriptase inhibitors (NNRTI) which are currently used to treat HIV patients," wrote investigators in France.
"All drugs are extracted after a liquid-liquid extraction and separated on a Cl 8 column with a binary gradient elution except lopinavir which is separated without this gradient. The absorbance is measured at 259 nm except for lopinavir (205 nm) and nevirapine (320 nm)," E. Dailly and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.